WEECO Pharma GmbH has agreed a three-year supply agreement with Cannasouth, one of the leading producers of medicinal cannabis in New Zealand. The company uses only pharmaceutical-grade ingredients to develop medicines that are unrivalled in terms of the purity, quality and potency of the cannabinoids.
Cannasouth cultivation is located on a 45-ha site in the heart of New Zealand’s Waikato region. Premium-plus GACP/GMP pharmaceutical-grade cannabis flowers are cultivated year-round in a state-of-the-art sealed controlled environment (CEA) greenhouse facility. Cannasouth exists to produce GMP certified medicinal products that are completely safe, highly effective, and clearly traceable in origin.
Boerge Diessel, CEO of WEECO Pharma GmbH comments “We are incredibly excited to be starting our partnership with Cannasouth. After a long vetting and qualification process, we are now able to add the top NZ supplier to our group of selected producers and genetics collaborators. Our customers will benefit from Cannasouth’s excellent quality produced in their state-of-the-art facility. We will develop products together that will enable clear advances to be made in the treatment of various illnesses and thus offer patients a better quality of life.”
Cannasouth CEO Mark Lucas says “We are thrilled to partner with WEECO and be a key part of their global network and growth plans. We have built a world-class team and world-class cultivation facility here in New Zealand. These strong foundations are now enabling us to reap the rewards of our efforts and participate as a key player on the international stage.”